Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Four years plus and holding. No gains, no losses, just holding, Grasshopper.
This is a valid concern. I agree, great news comes on Mondays, and bad news comes on Fridays. The last time I chimed in on a conference call, people had been speculating much the same as they are now--towards the positive side--and instead we were waylaid. I'm not expecting either way, I'm just going to make sure I have my fingers on the 'execute' button should I need it.
There are a lot of emotions floating around on this board. I threw five grand at this stock about three and a half to four years ago, thinking it might hold its own. I'm down about 50% today, but I have to say: that's pretty amazing. To lose only fifty percent of my money in that time on a R&D penny stock is fabulous. So, I say this puppy has legs! I don't care about "shady Kenny this and that," or " It's going to help so many people!" Whatever. I'm not here for any reason other than I placed a bet and I'm letting it ride until I'm not, lol. Check your emotions at the door, people. That 'Welcome' mat was intended for your sack.
Still hanging in there. I haven't visited this site in quite awhile, but it looks like it's time to start paying attention to my investment. :) Looking forward to today's meeting and upcoming events.
Well, I went from owning 400,000 shares that were once worth $12,000 to owning 800 shares that are currently worth $0.32. Boy did I call this one wrong. That dirty reverse split put a f'n to me and Lagan has been shoveling dirt on me ever since. I can't believe I was duped by this guy. I really thought he had the shareholder in mind at one point. I sure have a different perspective now. I can't believe I have to come out of pocket to sell. This company would have died long ago if it wasn't for their cunning ability to play shareholders. I'm disgusted.
Well this is a nice surprise. I was looking at the chart last week and thought "Hmm. Maybe I should pick up some more."
This is by far the worse I've ever had my backside handed to me. I should have and could have sold for over 500% when it hit $.03, but I stayed the course because I had friends show up late to the party (that I alerted them to) and I didn't want to be that guy. Seamus, on the other hand appears to be that guy. When that initial increase in OS went through, I knew right then what was going on; nothing above the board. I wish I would have told my friends and colleagues to cut and run at that point. I feel as though I've been cheated. I would have never imagined that there would be any merit to Bar's rantings. I stand corrected.
Still holding.
Wow, what a great surprise! I didn't even peek at the action today because business is off the hook lately. Nice to see today's chart. I'm thinking I missed my opportunity to double under $.005. Doh! I really thought it'd go a bit lower before turning. Oh well. Go RNVA!
Well, shoot. It finally brought me back to even. I guess I decided a ways back that I would hold through this slide, and probably double my position at this level. Hmm. It's tough to say, but I'm thinking I might get them a little cheaper yet, lol. Tough call here. I'm too busy lately to give much of a rat's ass about my position, at least until it gets my attention again. Staying the course. Still unshakeable (unless for some reason the acquisition falters, then I'm outta here with a loss.)
Still here. Unshakeable. I know what I own. GLTA
You've got to call a spade a spade, right?
Chart looks a little weak from the last several months. Looks like the recent volume has only yielded flippers. Any highlights beyond that?
Gonna start my DD here.
What's all the fuss about? It looks like perfectly normal trading to me. If you want instant gratification, grab a copy of Big 'Uns and head to the bathroom. These boards have never really been worth reading, but this one has become quite the pre-menstrual episode.
Exciting times! PMCB
The 15 min/3 day chart is lit.
It's odd that CDEL sat on the sidelines for a spell here. I wonder if we're bottoming out, even if we linger for awhile. I won't average up at this point, mostly because I don't average up buying dips etc., but part of me was hoping to double my position in the low .005's. Now I'm left wondering if that'll actually become a reality. And that doesn't mean I need one of you naysayers to tell me "IT'S TANKING TO .0001!!!!!!"
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--May 16, 2018--
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R) , today announced that the cells it will encapsulate and then use in its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) have successfully passed all 29 tests required by the U.S. Food and Drug Administration (FDA). Most of the tests were conducted by PharmaCyte's contractor, Eurofins Lancaster Laboratories, Inc. (Eurofins). The rest of the tests were conducted by third party laboratories subcontracted by Eurofins.
PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, commented, "We are pleased that the cells being used in our LAPC trial have now successfully passed all of the rigorous and extensive testing done on them by Eurofins and its subcontractors. The nature of the various tests was quite varied and some of the tests were more complex than others, so we're excited that the cells, which are at the heart of our pancreatic cancer therapy, could endure such a wide range of testing and pass each and every one. Now that testing is complete and all results are positive, we have been advised by Eurofins that we will have a final Certificate of Analysis next week. With this document in hand, the cell encapsulation process can begin."
Before any tests could be started, cells from the Master Cell Bank had to be thawed from frozen storage and then cultured to obtain enough cells for all of the planned tests. This was completed on January 24, 2018. In all, the cells underwent 29 different tests. Because of processes involved at Eurofins pertaining to the tests, not all tests could begin at the same time.
Once each test was completed, the test results had to be analysed and a report written by Eurofins. Then the conduct and results of each test had to examined and approved by Eurofins' Quality Assurance/Quality Control department. Now that all the tests have been successfully completed, Eurofins is preparing the necessary Certificate of Analysis to be sent to Austrianova in Thailand where encapsulation will be performed using PharmaCyte's signature live-cell encapsulation technology. Having the Certificate of Analysis is a cGMP requirement before encapsulation can begin.
About PharmaCyte Biotech PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box(R) ." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte's therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient's tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a "bio-artificial liver" and activate the chemotherapy drug at the site of the cancer. This "targeted chemotherapy" has proven effective and safe to use in past clinical trials and results in no treatment related side effects. PharmaCyte's therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body and/or beta islet cells. The encapsulation will be done using the Cell-in-a-Box(R) technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a "bio-artificial pancreas" for purposes of insulin production. Safe Harbor This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission. More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte's Investor Relations Department. View source version on businesswire.com: https://www.businesswire.com/news/home/20180516005682/en/ CONTACT: PharmaCyte Biotech, Inc. Dr. Gerald W. Crabtree Investor Relations Department 917-595-2856 Info@PharmaCyte.com SOURCE: PharmaCyte Biotech, Inc. Copyright Business Wire 2018 (END) Dow Jones Newswires May 16, 2018 09:30 ET (13:30 GMT) Story ID: 20180516SN009736 Keywords: COMPANY NEWS, THIRD-PARTY CONTENT, PRESS RELEASES AUTO-PUBLISHED ON TICKER, DOW JONES CONTENT SET SN, PRESS RELEASE WIRES, PRESS RELEASES ON NEWSWIRES, CHEMICALS-ALL, GRAND CENTRAL ASSET CLASS EQUITIES, BUSINESS WIRE, BASIC MATERIALS, SIGNIFICANT STORY Symbols: PMCB
Just curious, but how could your average be at the all time low ($.004), especially when you started buying last November?
Well timed. CDEL is just about to run out of shares, too. Good Luck!
We've traded 326 million shares in the last four days. I suspect that 179,000,000 will clear by EOD, today.
Still unshakeable. No fear here. Not effected by ridicule or nay-saying. Like I’ve said. If it works it’s way to the 52 week low without piercing it, I’m doubling my position. Carry on.
Hmm. It's not looking like I'll get my $.005's. I think she's about to curve back up.
Agree. That was pretty effed.
You can delete my posts, but not my integrity.
The spin-off's are projected to be "in the coming months," not in the next couple of weeks.
I'm not saying they didn't stack the deck, but I'm not saying they did either. The evidence isn't in front of me, and quite frankly, I'd rather it wasn't if it means my potential for gains will be interrupted. I think you're awfully bold to outright claim fraud. I thought you were awfully bold with your claims of a hostile takeover in the works also. You have a tendency to present your claims with utmost certainty, which is probably just as illegal as RNVA stacking the deck. You're going to do what you're going to do, but I will caution you that even with a split personality, you're on the hook for at least half of what you say.
I couldn't agree more, believe me. But as a seasoned trader, I take full responsibility for my gamble, as should you, despite what is said by one person or many. The truth is, the float was a lock, it was. That was attractive. Some posters were rallying investors to vote no on the RS and the increase in AS, and I was in support of those efforts (though not vocally). All of us knew all along that both the RS and the AS vote could go against us. The greater evil was destroyed without haste and the AS passed by a small margin (probably by those who had sold their positions but retained voting power and thought it best for the benefit of the company).
Here's the thing: it's all in the past. It's done. It isn't on the table. What is on the table is how the company manages the issuance of shares from this point forward, and the "intended" acquistion date formerly known as being a hard date. If RNVA can come through on the acquisiton and minimize the issuance of shares, we should absolutely confirm the trend upward.
Sure, I can look back and say I should have sold at $.03 when I saw all that cash in the coffers, but I didn't. And that's that. I'm here now with much less gains and I'm holding.
We have to let the momentum of CDEL's sell pressure play through for a bit before we can swing the other way.
Agree, 100%. My bottom line is what matters to me.
Of course, I can't say that definitively. However, it's awfully suspect. It's not SOP for RNVA to report share distributions two months after the fact, and when you consider the transfer date of 3/06, and the shareholder of record date of 3/12, well, that's three highly suspicious marks. In my twenty years of trading I've seen a lot of gray area moves by OTC companies, and I've never raised a flag or filed a complaint. I would not be surprised if we come to learn of some malice with this particular coincidence.
IMO, it looks like someone decided to retroactively issue some voting power the day before the meeting, and pre-date the issuance within the prescribed window.
Agreed. The effective date of the AS increase was 5/09, I noticed. No haste there.
School will be in session at any minute. What's being taught? We shall soon find out.
Bands on the 15 are tightening fast.
IMO, whichever way the next move, it's big.
I don't like being down $10K+ off my highs, but I'm not selling. I'm of the opinion that this stock is undervalued as it is, and they always find their place eventually. Long and strong. That's not to say I can't be shaken, because at $.0046 I'm either doubling my position, or taking a small loss. In any event, I enjoy the adventure.
I'll get the last laugh.
The infamous CDEL 10K infinity well.